ClinicalTrials.gg
Enrolling by invitationNCT05346016Updated Oct 2, 2026

The PEARL-AGE Study. Multigenerational Gut Bacteria Transmission and Its Stability in Families.

An observational study in Family Research, sponsored by Quadram Institute Bioscience. Enrolling by invitation at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Quadram Institute Bioscience · Observational

How we know

Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Sex
All
01

Study summary

Investigators will recruit up to 4-generations of human family cohorts, in order to characterize the microbiome and its changes across different generations.

Read the detailed description

Interest in the gut microbiome from both the scientific community and public has increased exponentially over the last decade. Yet our knowledge of the microbes in the gut microbiome, their persistence and dispersal to new human hosts is still surprisingly ill-defined.

Investigators hypothesize that some gut microbes persist over multiple generations and are adapted to varying degrees to their human hosts and families, making them potentially important members of the human gut. Bacterial strains can persist in the human host for years, with maternally-transferred strains known to persist longer in infants than environmentally acquired ones. It is conceivable that a given strain can colonize a host for several vertical generations, as already shown for Bifidobacterium using cultured isolates. Yet investigators currently lack knowledge of microbial persistence over multiple generations, and the proposed PEARL-AGE cohort is the first study investigating multi-generation persistence of gut bacteria (to our best knowledge).

The PEARL-AGE project will investigate microbial transfer and the evolution of microbes in family members from different generations. Investigators will recruit siblings, fathers/guardians, grandparents, and great-grandparents to fully capture vertical (between generations) and horizontal (same generation) microbial transmission across multiple generations, as well as tracking parallel microbial evolution in multiple family members. This will substantially increase our understanding of microbial transmission, long-term microbial persistence through generations and between cohabiting family members and siblings.

02

Conditions studied

  • Family Research

Keywords

  • gut microbiome
  • microbial adaptation
  • microbial evolution
03

In context

Lead sponsor

Quadram Institute Bioscience is the lead sponsor of 44 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Investigators are recruiting the family members of PEARL (ClinicalTrials.gov ID: NCT03916874) study participants, a longitudinal study to understand how gut microbes contribute to maintaining health during pregnancy and early life already underway at QIB (Quadram Institute Bioscience). Investigators will extend this cohort, by recruiting family members of the PEARL mother to form the PEARL-AGE cohort, extending it from two generations to four generations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The following relations of the PEARL mother/baby are eligible for inclusion:

    • Husband/partner of a PEARL mother, their biological parents and grandparents.
    • PEARL mother's biological parents and grandparents (great-grandparents to the PEARL baby).
    • Co-habiting non-biological fathers of the baby such as stepfathers and partners of the PEARL mother, their parents and grandparents.
    • A biological sibling of the PEARL baby or a step-sibling who is currently co-habiting with the PEARL baby.
  • Adult participants must be able to consent for themselves and able to understand the questionnaire.
  • Child participants must have a parent and/or guardian to provide assent on their behalf.
  • Must be living in England.
  • Must be willing to accommodate a small cool box to store and transport the biological samples until they are collected, if not having immediate access to the PEARL study freezer.
  • Vulnerable participants such as participants with mild cognitive impairment may be included as long as they have full support from their family members.

Exclusion criteria

Exclusion Criteria:

  • Not related/affiliated to a mother currently participating in the PEARL study, or the cohabiting partner, or father of the PEARL infant. If a PEARL participant has withdrawn from the PEARL study or is no longer participating, investigators will not approach the PEARL participant for recruitment of their family members.
  • Step-fathers or long-term partners that have been cohabiting with the PEARL mother for less than three months.
  • Those currently in prison.
  • Those who are unable to provide written .
  • Living with or related to a member of the Research Study team.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Characterizing microbial transfers in multigenerational families and subsequent stability of microbial colonization.

    High-resolution metagenomics of strains tracked over time in individuals and families, relative to collected metadata (family closeness, medical history, etc) Associating microbiome stability to human genetic loci.

    Time frame: 2026

Secondary outcomes

  1. Characterizing gut microbial evolution and adaptation in human host families.

    Comparative genomics of metagenome assembled genomes (MAGs) per individual. Identifying newly introduced mutations in microbial genomes. Observing parallel evolution (e.g., loss or gain of the same genes in bacteria). Associating human genotypes to microbial adaptation.

    Time frame: 2026

Other outcomes

  1. Describing the prokaryotic and eukaryotic genome-level diversity within the human gut

    Newly developed DNA extraction protocols for enrichment of specific microbial clades.

    Time frame: 2024

  2. Identify predictors of within-family gut microbe transfer rates

    Correlation coefficient of collected metadata (questionnaire derived) to observed shared microbes Correlate parallel colonization's of sibling to family questionnaire metadata (e.g. distances, closeness, habits, ..) Correlate genetic factors (immune system, etc) to microbial sharing/colonization rates

    Time frame: 2026

07

Study locations

1 site
  • Quadram Institute Biosciences
    Norwich, Norfolk NR4 7UQ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2022 (actual). Primary completion is estimated for Mar 2030, 96 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Mar 2026 → Mar 2030 and completion Mar 2026 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2022
First posted
Apr 26, 2022
StartActual
Mar 18, 2022
Primary completionEst.
Mar 2030was Mar 2026
CompletionEst.
Mar 2030was Mar 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2026→Mar 2030
Oct 2, 2026
Study completion
Mar 2026→Mar 2030
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Mar 2026→Mar 2030
    Study completion Mar 2026→Mar 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05346016
Lead sponsor
Quadram Institute Bioscience
Collaborators
Earlham Institute, Norfolk and Norwich University Hospitals NHS Foundation Trust, Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Mar 18, 2022
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 2, 2026

Study contacts

Falk Hildebrand, PhD
principal investigator · Quadram Institute Bioscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion